CurifyLabs, a Helsinki-based HealthTech company transforming how personalised medicines are made, today announced the closing of a €12 million ($14 million) Series A round to expand U.S. operations, strengthen supply chain infrastructure, enhance customer support, and accelerate product innovation.
The round was co-led by Sandwater and HealthCap, with participation from Tesi (Finnish Industry Investment Ltd.) and existing investors, including Lifeline Ventures. This follows their €6.7 million raise in May 2025.
“This investment reflects the conviction our partners have in what we’re building,” says Charlotta Topelius, CEO and founder, CurifyLabs. “We have set a high bar for clinical rigor, product quality, and customer support, and this funding gives us the resources to raise that bar further.”
CurifyLabs’ Series A follows a series of 2026 HealthTech, MedTech and life sciences infrastructure financings focused on personalised health, diagnostics, clinical workflow automation and healthcare supply chains.
Adjacent rounds include Rem3dy Health’s €16 million raise for personalised health expansion, ShanX Medtech’s €24 million financing for antimicrobial-susceptibility diagnostics, Xyall’s €7.6 million round for automated molecular pathology workflows, SamanTree Medical’s €20 million EIB financing for surgical imaging, ScreenPoint Medical’s €13.6 million raise for AI-powered breast cancer detection, BioLamina’s €20 million EIB loan for cell-therapy infrastructure, Helical’s €8.4 million Seed round for pharma R&D software, and Astral Systems’ €26 million Series A for medical-isotope supply infrastructure.
These 2026 adjacent announcements amount to approximately €137 million in disclosed funding, or around €149 million including CurifyLabs’ new round.
“Personalised medicine is one of the most important frontiers in healthcare enabling better patient outcomes and is experiencing solid growth. We are enabling more pharmacies to deliver personalized medicine in a safer and more efficient way“, adds Morten E. Iversen, partner at Sandwater. “CurifyLabs has built something rare – technology that combines clinical rigor with the speed and precision that busy pharmacy teams depend on. We are excited to support their rapid growth in the U.S. and beyond.”
Founded in 2021, CurifyLabs’ Compounding System Solution (CSS) combines proprietary software, GMP-manufactured excipient bases, and advanced 3D printing technology to automate the preparation of personalised medications.
Pharmacies in 21 U.S. states and across Europe use CurifyLabs technology to compound and dispense thousands of doses daily.
“We have backed more than 136 life sciences companies over nearly three decades, and what sets the best founders apart is their ability to combine scientific depth with real-world execution,” says Daniel Karsberg, partner at HealthCap. “The CurifyLabs team has done exactly that.”
The funding will support ongoing development of the CurifyLabs platform, including its most recent product, the PharmaPrinter Aurum, which reportedly compounds up to nine times faster than manual processes.
CurifyLabs’ technology is ISO 13485 certified and designed in compliance with FDA 503A/503B standards for non-sterile compounding.
“CurifyLabs is the kind of company we want to support – innovative, globally ambitious, and built on deep scientific expertise,” says Joni Karsikas, Investment Director at Tesi. “Their growth in the U.S. is further proof that Finnish health technology can compete and win on the world stage.”
Read the orginal article: https://www.eu-startups.com/2026/07/finlands-curifylabs-raises-e12-million-to-expand-3d-printing-based-medicine-compounding/
